– Phase 3 Clinical Trial Data Show Efficacy of BARHEMSYS in Treatment of Post-Operative Nausea & Vomiting Cambridge, UK and Indianapolis, US - Acacia Pharma Group plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH) announces that data and analyses from its positive Phase 3 clinical…
– Breath Therapeutics Appoints Noreen Roth Henig, M.D. as Chief Medical Officer - Dr. Henig adds leadership and development expertise in pulmonary disease, inhaled therapies, and orphan disease to the executive management team - Breath Therapeutics is targeting Bronchiolitis Obliterans…
– Cambridge, UK and Indianapolis, US - Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has secured a credit facility of up to $30 million with Hercules…
– The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a first-in-class potential therapeutic RNA molecule designed to improve the healing and integrity…
– LEXINGTON, Mass. and AMSTERDAM, the Netherlands (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has enrolled its first patient in the Phase III HOPE-B…
– Gilde Healthcare has announced that they have transferred their shares in the physiotherapy chain Fysius Back Clinics to AAC Capital. With the support of Gilde Healthcare, Fysius has grown into a national chain with 29 locations specialized in back care. Fysius is a chain of treatment…
– 's-Hertogenbosch, The Netherlands - Lava Therapeutics ("LAVA") today announced it has raised EUR 16 million in its first major institutional financing round from an investor syndicate led by Gilde Healthcare. The funding will support development of LAVA's proprietary pipeline of bispecific…
– Irvine, US - Inari Medical, a portfolio company of Gilde Healthcare, announced that its FlowTriever System has received FDA 510(k) clearance for the treatment of pulmonary embolism ("PE"). This clearance makes the FlowTriever System the first and only thrombectomy device cleared by…
– Utrecht, The Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired NightBalance, a portfolio company from specialist investor Gilde Healthcare. Netherlands-based NightBalance is a digital health scale-up company…
– Utrecht, The Netherlands - Gilde Healthcare announced it has sold its shareholding in molecular diagnostics STAT-Dx (Barcelona, Spain) to QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA). QIAGEN has agreed to acquire all shares of STAT-Dx for $147 million in cash and additional…
– Multicenter FLARE Study for PE Treatment IRVINE, CALIFORNIA – Inari Medical, Inc., announced today the presentation of results from its FlowTriever Pulmonary Embolectomy ("FLARE") Clinical Study that evaluated the safety and effectiveness of the FlowTriever Retrieval/Aspiration System…
– Utrecht, The Netherlands - Gilde Healthcare portfolio company RAD-x, the pan-European operator in diagnostic imaging, has announced that it has acquired Teleradiologisches Zentrum Koblenz (TelradKo). TelradKo provides teleradiology services to hospitals and hospital-based imaging…
– Equity Round of $20 million led by Longitude Capital with Silicon Valley Bank Providing a $20 million Credit Facility Irvine, CA – Axonics Modulation Technologies, Inc., a privately-held developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment…
– Utrecht, The Netherlands - AM-Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today announced positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney…
– Palma, Spain and San Diego, USA - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today the completion of its Phase II clinical trial of SNF472, its lead candidate for the treatment of the orphan disease…
– With a EUR 190 million market cap, Acacia Pharma realizes the largest new healthcare listing on Euronext in two years. Utrecht, The Netherlands - Acacia Pharma Group plc announces its Initial Global Offering and listing on Euronext Brussels. Shares in the Initial Global Offering…
– Utrecht, The Netherlands - RAD-x, a France-based operator in diagnostic imaging and a portfolio company of Gilde Healthcare, announced that it has acquired Swiss Medical Imaging Investment SA (SMII), which operates the imaging centres Centre d'Imagerie Médicale de la Chaux-de-Fonds,…
– Gilde Healthcare today announces the acquisition of Performation, market leader in business intelligence for healthcare in the Netherlands. The investment will facilitate the expansion of the company's service offering to healthcare clients.
– Utrecht, The Netherlands – Gilde Healthcare announces today that QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated…
– Dublin, Ireland – Foundry Innovation & Research 1, Ltd. ("FIRE1"), today announced the close of a Series C financing totaling EUR 40 Million($48.5 Million). The financing was led by Gilde Healthcare with the participation of Gimv, Seventure, New Enterprise Associates, Lightstone Ventures…
– Cambridge, UK and Indianapolis, US – Acacia Pharma, the specialist pharmaceutical company developing and commercialising hospital products for US and international markets, announces that the New Drug Application (NDA) for BAREMSIS® for the management of post-operative nausea & vomiting…
– The Hague, the Netherlands – NightBalance, a leader in innovative obstructive sleep apnea therapies, today announced that the Dutch National Health Care Institute (ZIN) issued a positive recommendation to include its sleep apnea therapy for reimbursement. The Sleep Position Trainer…